Barinthus Biotherapeutics (NASDAQ:BRNS) Price Target Raised to $4.00

Barinthus Biotherapeutics (NASDAQ:BRNS) had its price target raised by HC Wainwright from $3.00 to $4.00 in a report released on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ FY2025 earnings at ($1.77) EPS and FY2026 earnings at ($1.42) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Barinthus Biotherapeutics in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Trading Up 2.4%

Shares of NASDAQ BRNS opened at $0.73 on Monday. The firm has a market capitalization of $29.80 million, a price-to-earnings ratio of -0.39 and a beta of -0.70. Barinthus Biotherapeutics has a one year low of $0.64 and a one year high of $2.92. The business has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $1.14.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Friday, November 7th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. On average, research analysts anticipate that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC bought a new position in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned about 0.09% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.